A
Ana M. Gamero
Researcher at Temple University
Publications - 57
Citations - 2751
Ana M. Gamero is an academic researcher from Temple University. The author has contributed to research in topics: Interferon & STAT1. The author has an hindex of 27, co-authored 52 publications receiving 2384 citations. Previous affiliations of Ana M. Gamero include University of South Florida & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells
Claudia U. Duerr,Connor D A McCarthy,Barbara C. Mindt,Manuel Rubio,Alexandre P. Meli,Julien Pothlichet,Megan M. Eva,Jean-François Gauchat,Salman T. Qureshi,Bruce Mazer,Karen L. Mossman,Danielle Malo,Ana M. Gamero,Silvia M. Vidal,Irah L. King,Marika Sarfati,Jörg H. Fritz +16 more
TL;DR: It is found that deficiency in signaling via type I interferon receptor led to deregulated activation of group 2 innate lymphoid cells (ILC2 cells) and infection-associated type 2 immunopathology.
Journal ArticleDOI
Interferon: Cellular Executioner or White Knight?
TL;DR: The role of specific signaling molecules and the function(s) of particular IFN-stimulated genes that have been implicated in determining cell fate in response to IFN are highlighted, as well as the clinical experience of IFN immunotherapy.
Journal ArticleDOI
Cecal Ligation Puncture Procedure
TL;DR: To understand sepsis at various levels it is crucial to have a suitable and comprehensive animal model that reproduces the clinical course of the disease and control the model conditions for testing potential therapeutic agents.
Journal ArticleDOI
IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity.
Stephen G. Maher,Faruk Sheikh,Anthony J. Scarzello,Ana L. Romero-Weaver,Darren P. Baker,Raymond P. Donnelly,Ana M. Gamero +6 more
TL;DR: It is demonstrated that the duration of IFN-λ signaling is different from that of IFn-α, and that IFN -λ could be a suitable cytokine to evaluate for cancer therapy.
Journal ArticleDOI
Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages
Scott McComb,Erin Cessford,Norah A. Alturki,Julie Joseph,Bojan Shutinoski,Justyna B. Startek,Ana M. Gamero,Karen L. Mossman,Subash Sad +8 more
TL;DR: The results indicate that in order to undergo necroptosis, immune cells must produce and receive signals from the key immune regulator, interferon, and reveal how IFN-I mediates acute inflammation through macrophage ne croptosis.